What is the normal blood concentration of Pulekefu

Precopar prevents graft rejection after liver or kidney transplantation. Treatment of graft rejection that cannot be controlled by other immunosuppressive drugs after liver or kidney transplantation. At the molecular level, the effect of Plexitacrolimus is obviously to combine with cellular protein (FKBP12) and accumulate in cells to produce its effect. Today, let’s take a closer look at what is the normal blood concentration of Puraco?

Preclosumab, named by the laboratory: FK506, is an immunosuppressant commonly used in clinical medicine to prevent allograft rejection after liver transplantation (including liver, kidney function, heart and pancreas) and diseases that require immunosuppressive treatment, such as lupus nephritis, membranous nephropathy, focal segmental tubular sclerosis and subtle lesions.

Excessive plasma concentration of Precorefk506 may cause side effects such as headache, diarrhea, high blood pressure, nausea and vomiting. For ordinary people, the blood concentration value of Preclosumab Fk506 is between 4 and 6. However, after transplantation, the blood concentration of Precos® Fk506 will be slightly higher, above 6, and will gradually decrease after treatment.

The bacterial and viral infection rate of patients taking Proclospora is also lower than that of patients treated with cyclosporine. In particular, this product has strong hepatotropic properties and is 100 times more effective in liver transplantation. Therefore, the clinical dosage is greatly reduced, and the original treatment cost can be reduced by 1/3 to 1/ 2 (Patients using this product can be discharged from the hospital 2 weeks after surgery while those using cyclosporine need 4 weeks). At the same time, adverse reactions are also significantly reduced. It has the advantages of low mortality, high transplant survival rate, good graft success rate and relative independence from steroids.

The immunosuppressive effect of Preclosumab is tens to hundreds of times that of cyclosporine in both in vitro and in vivo tests. Clinically, a concentration of 1% of Preclosumab is effective.

In addition, Preclosumab is better than cyclosporine in inhibiting rejection reactions that have already occurred. In the past immunosuppressive regimens based on cyclosporine, the problem of irreversible chronic rejection remained the same. Although increasing the dose had further effects, it also brought serious adverse reactions. Preclosumab is expected to reduce acute and chronic rejection in liver and kidney transplant recipients.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: